asct remains at the forefront of multiple myeloma therapy
Published 5 years ago • 78 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
2:55
the discovery of pathogenic germline variants in patients with myeloma
-
1:25
predictors and outcomes of extramedullary disease in multiple myeloma
-
4:06
addressing the challenge of post-asct relapse in multiple myeloma & the value of precision medicine
-
2:40
asct in relapsed myeloma patients
-
1:53
canova trial: vendex versus pomdex in patients with r/r multiple myeloma
-
5:59
what is hrmm (high-risk multiple myeloma)?
-
4:51
the current frontline treatment strategy in multiple myeloma
-
2:38
how close is a cure for multiple myeloma?
-
1:53
the future of multiple myeloma treatment
-
3:34
maintenance therapy following salvage asct for multiple myeloma
-
2:00
real-world outcomes of autosct for multiple myeloma in the first-line setting
-
1:44
optimal treatment sequencing in multiple myeloma
-
3:50
evolution of autosct in multiple myeloma: patient demographics and improved outcomes
-
4:46
does asct still have a place in myeloma treatment?
-
10:42
a detailed overview of the current and emerging gene therapies for hemophilia a & b
-
2:46
managing patients with high-risk myeloma
-
1:09
using mrd and pet/ct to assess responses post-asct in myeloma
-
2:15
the management of multiple myeloma in 2021
-
2:44
myeloma qol through induction and maintenance
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
2:42
results from majestec-1: health-related quality of life with teclistamab in patients with r/r mm
-
3:06
multiple myeloma: adcs and bites